Osage University Partners I LP

Official name: 
Osage University Partners I Limited Partnership

Corporate Profile

Registration country: 
United States
Overview 
Osage University Partners ("OUP") is a venture capital fund that invests in university start-ups. OUP partners with high quality universities to serve as their coinvestment vehicle in start-ups that are licensing their technology. When universities license their technology to start-ups, the university frequently receives equity and participation rights, which is the right to participate in the future financing rounds of a start-up. Historically, universities rarely exercised their preemptive rights or otherwise invested in the institutional financing rounds of their own companies. OUP and its partner universities have created a fund to exercise each university's participation rights, and if there are no participation rights to participate as a co-investor on behalf of the university. Osage and its partner universities share in the profit of the fund, so each university has an incentive to help increase the equity value of its start-ups. OUP invests across all sectors of university commercialization, including life sciences, physical sciences, and information technology. Osage invests broadly across stage, from seed to late stage, in venture capital rounds of start-ups alongside new lead investors. By virtue of its university partnerships, OUP focuses primarily on the start-ups from its university partners, and it does not actively review non-university investment opportunities. OUP develops close working relationships with each university's start-ups prior to their fundraising and tracks each company's progress over time. OUP can assist these start-ups prior to an investment by providing fundraising guidance, introductions, or other assistance. Once an investment opportunity arises, OUP already knows the company and management well and can make a fast, informed investment decision.

Key fund terms

Fund manager: Osage Partners LLC
Fund type: venture
Vintage: 2011

Fund Capital and Status

Final Closing 24th Feb 2011 USD 100,000,000
Target USD 100,000,000

Investment Preferences

Sample Investments

Company Profile Amount Industry Ctry Stage Date
Aerie Pharmaceuticals Inc USD Pharmaceuticals US Series B Mar 2011
Cleave Biosciences Inc Drug development company focused on novel targets in cellular protein homeostasis pathways USD Biotechnology US Series A Nov 2011
SolarBridge Technologies Inc Renewable Energy Equipment US Series D May 2012

Current employees

No current employees available

add an employee

RECORD ID: 138862